Adjuvant taxanes in the treatment of breast cancer: No longer at the tip of the iceberg

Clinical Breast Cancer

Volumn 7, Issue 1, 2006, Pages 51-58

  Dang, Chau ^a   Hudis, Clifford ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Chemotherapy; Docetaxel; Hormone receptor status; Paclitaxel

Indexed keywords

ANTHRACYCLINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ERYTHROPOIETIN; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PACLITAXEL; PREDNISOLONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB; VINCRISTINE;

ANEMIA; BLOOD TOXICITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER RELAPSE; CANCER STAGING; CLINICAL TRIAL; CONSENSUS; DISEASE FREE SURVIVAL; DRUG DOSE REGIMEN; HUMAN; REVIEW; RISK REDUCTION;

EID: 33744988303     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2006.n.013     Document Type: Review

References (32)

1. Greenlee RT, Murray T, Bolden S, et al. Cancer statistics, 2000. CA Cancer J Clin 2000; 50:7-33.
2. Fisher B, Foster R, Gardner B, et al. Relation of positive axillary nodes to the prognosis of patients with primary breast cancer. Cancer 1983; 52:1551-1557.
3. Fornier M, Munster P, Seidman A. Update on the management of advanced breast cancer. Oncology 1999; 13:647-658.
4. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Lancet 2005; 365:1687-1717.
5. National Institutes of Health Consensus Development Panel: National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1, 2000. J Natl Cancer Inst Monogr 2001; 93:979-989.
6. Goldhirsch A, Glick, JH, Gelber RD, et al. Meeting highlights: international consensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005; 16:1569-1583.
7. Nabholtz JM, Falkson C, Campos D, et al. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first line therapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol 2003; 21:968-975.
8. Jassem J, Pienkowski T, Pluzanska A, et al. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. J Clin Oncol 2001; 19:1707-1715.
9. Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003; 21:976-983.
10. Mamounas EP, Bryant J, Lembersky BC, et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP-B 28. J Clin Oncol 2005; 23:3686-3696.
11. Albain KS, Green SJ, Ravdin PM, et al. Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent: initial results from intergroup trial 0100 (SWOG-8814). Proc Am Soc Clin Oncol 2002; 21:37a (Abstract #143).
12. Buzdar AU, Singletary SE, Valero V, et al. Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial. Clin Cancer Res 2002; 8:1073-1079.
13. Martin M, Rodriguez-Lescure A, Ruiz A, et al. Multicenter, randomized phase III study of adjuvant chemotherapy for node positive break cancer comparing 6 cycles of FE90 C versus 4 cycles of FE90 C followed by 8 weekly paclitaxel administrations: interim efficacy analysis if GEICAM 9906 Trial. Breast Cancer Res Treat 2005; 94(supp 1):S20 (Abstract #39).
14. Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup trial C9741/Cancer and Leukemia Group B trial 9741. J Clin Oncol 2003; 21:1431-1439.
15. Hudis C, Citron M, Berry D, et al. Five year follow-up of INT C9741: dose-dense chemotherapy is safe and effective. Breast Cancer Res Treat 2005; 94(suppl 1):S20 (Abstract #49).
16. Citron ML, Berry DA, Cirrincione C, et al. Dose-dense (DD) AC followed by paclitaxel is associated with more frequent moderate anemia compared to sequential (s) and/or less DD treatment: update by CALGB on Breast Cancer Intergroup trial C9741 with ECOG, SWOG, and NCCTG. Proc Am Soc Clin Oncol 2006; 24:33s (Abstract #620).
17. Berry DA, Cirrincione C, Henderson IC, et al. Effects of improvements in chemotherapy on disease-free and overall survival of estrogen receptor negative, node-positive breast cancer: 20-year experience of the CALGB & U.S. Breast Intergroup. Breast Cancer Res Treat 2004; 88(suppl 1):S17 (Abstract #29).
18. Martin M, Pienkowski T, Mackey J, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005; 352:2302-2313.
19. Goldstein LJ, O'Neill A, Sparano JA, et al. E2197: phase III of AT vs AC in the adjuvant treatment of node-positive and high-risk node-negative breast cancer. J Clin Oncol 2005; 23(16 suppl):7s (Abstract #512).
20. Jones SE, Savin MA, Holmes FA, et al. Final analysis: TC (docetaxel/ cyclophosphamide, 4 cycles) has a superior disease-free survival compared to standard AC (doxorubicin/cyclophosphamide) in 1016 women with early stage breast cancer. Breast Cancer Res Treat 2005; 94(suppl 1):S20 (Abstract #40).
21. Roche H, Fumoleau P, Spielmann M, et al. Five years analysis of the PACS 01 trial: 6 cycles of FEC 100 vs 3 cycles of FEC 100 followed by 3 cycles of docetaxel (D) for the adjuvant treatment of node-positive breast cancer. Breast Cancer Res Treat 2004; 88:S16 (Abstract #27).
22. Bear HD, Anderson S, Smith RE, et al. A randomized trial comparing preoperative doxorubicin/cyclophosphamide (AC) to preoperative AC followed by preoperative docetaxel (T) and to preoperative AC followed by postoperative T in patients with operable carcinoma of the breast: results of NSABP B-27. Breast Cancer Res Treat 2004; 88(suppl 1):S16 (Abstract #26).
23. Heys SD, Hutcheon AW, Sarkar TK, et al. Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial. Clin Breast Cancer 2002; 3(suppl 2):S69-S74.
24. Wolmark N, Wang J, Mamounas E, et al. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 2001; 30:96-102.
25. Sparano JA, Wang M, Martino S, et al. Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in patients with axillary node-positive or high risk node-negative breast cancer: results of North American Breast Cancer Intergroup trial E1199. Breast Cancer Res Treat 2005; 94(suppl 1):S20 (Abstract #48).
26. Green MC, Buzdar AU, Smith T, et al. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once very 3 weeks. J Clin Oncol 2005; 23:5983-5992.
27. Seidman AD, Berry D, Cirrincione C, et al. CALGB 9840: phase II study of weekly (W) paclitaxel (P) via 1-hour (h) infusion versus standard (S) 3 h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC. Proc Am Soc Clin Oncol 2004; 23:6S (Abstract #512).
28. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER-2 positive breast cancer. N Engl J Med 2006; 353:1673-1684.
29. Perez EA, Suman VJ, Davidson N, et al. Interim cardiac analysis of NCCTG 9831 Intergroup adjuvant trastuzumab trial. J Clin Oncol 2005; 23(16 suppl):17s (Abstract #556).
30. Slamon D, Eiermann W, Robert N, et al. Phase III trial comparing ACT with AC-TH with TCH in the adjuvant treatment of HER2 positive breast cancer patients: first interim efficacy analysis. Breast Cancer Res Treat 2005; 94(suppl 1):S5 (Abstract #1).
31. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2 positive breast cancer. N Engl J Med 2005; 353:1659-1672.
32. Miller K, Wang M, Gralaw J, et al. A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for